Advice

following a full submission considered under the ultra-orphan and end of life process: 

durvalumab (Imfinzi®) is accepted for use within NHSScotland.

Indication under review: as monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.

Durvalumab, compared with placebo, improved progression-free survival and overall survival in adults who have locally advanced unresectable NSCLC with PD-L1 expressed on ≥1% of tumour cells and disease that has not progressed following platinum-based chemoradiation therapy.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of durvalumab. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
durvalumab (Imfinzi)
SMC ID:
SMC2156
Indication:
as monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express programmed cell death ligand 1 (PD-L1) on ≥1% of tumour cells (TCs) and whose disease has not progressed following platinum-based chemoradiation therapy (CRT)
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published:
10 June 2019